Content generated by AI editorial engine. Editorially supervised by Sedat ANAK.
The Procter & Gamble Company
PG - NYSE - $146.99 ▲ +%0.13
-
Earnings
Fri 23 Oct
Procter opens the
books on Friday evening.
4 analysts' median target is $162[FMP target], stock is $147, +10.2% vs the analyst consensus median. After Q3 +1.4% EPS beat[FMP earnings], the stock moved -1.5%.
↓
summary below
Quick Take - in 40 seconds
B+
HOLD
Council 2/6
-
Moonshot 43
B+ = MoonshotScore 43[multi-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Quick AnswerThe Procter & Gamble Company (PG)
Q1 consensus: revenue $22.7B[FMP est], EPS $1.90[FMP est]. 6 consecutive quarters of beat[FMP earnings].
$1.90
EPS Estimate
Last year $1.99 - -5% YoY YoY
4%
Skin and Personal Care Guidance
Previous quarter was 3%
6
Beat Streak
Expectations beaten consecutively for the last 6 quarters
Q3 EPS +1.4% beat[FMP] but the stock -1.5% D+1[FMP D+1].
Dividend Increase Shareholder Returns
dividend_increase_shareholder_returns
P&G increased its dividend by 3%, continuing its commitment to return cash to shareholders, and plans to return approximately $15 billion in cash to shareowners in FY26.
"Earlier this month, we announced a 3% increase in our dividend, continuing our commitment to return cash to shareowners, and this marks the seventh consecutive annual dividend increase and the 136 consecutive year P&G has paid a dividend. ... We expect to pay around $10 billion in dividends and to repurchase approximately $5 billion of common stock, combined a plan to return roughly $15 billion of cash to shareowners at fiscal '26."
- Andre Schulten - Q3 FY26 Earnings Call - April 24, 2026
$150 million
Investor Focus
Middle East Conflict Cost Impact
middle_east_conflict_cost_impact
An additional after-tax cost of approximately $150 million is expected for FY26 due to commodity, feedstock, and logistics disruptions from the Middle East conflict, with most of this impact occurring in the fourth quarter.
"We now expect a headwind of approximately $150 million after tax for the fiscal from a combination of commodity-linked cost inflation, feedstock exposures and logistics disruptions resulting from the conflict in the Middle East. Almost all of these increased costs will be in the fourth -- fiscal fourth quarter."
- Andre Schulten - Q3 FY26 Earnings Call - April 24, 2026
Capex Increase
capex_increase
P&G expects an increase in capital spending to add capacity in several categories and to incur cash costs from restructuring work.
"This includes an increase in capital spending as we add capacity in several categories and as we incur the cash costs from the restructuring work."
- Andre Schulten - Q3 FY26 Earnings Call - April 24, 2026
Fy26 Eps Guidance Lower End
fy26_eps_guidance_lower_end
The company revised its core EPS outlook for FY26 towards the lower end of the guidance range due to geopolitical dynamics and increased costs.
"Given all the above, we now expect full year EPS results to be towards the lower end of the guidance range."
- Andre Schulten - Q3 FY26 Earnings Call - April 24, 2026
Strategy Superiority Productivity
strategy_superiority_productivity
The company continues to focus on product superiority, innovation, demand creation, and productivity improvements to gain a competitive advantage in challenging market conditions.
"As we move forward, we remain committed to the integrated growth strategy, a portfolio of daily use products and categories where performance matters. In these performance-driven categories, we must deliver irresistibly superior products across the product itself, the package, the brand communication, retail execution and value. We continue to drive productivity with multiyear visibility to fund innovation and demand creation and to mitigate cost headwinds."
- Andre Schulten - Q3 FY26 Earnings Call - April 24, 2026
Stock Expert AI - Methodology
Do our scoring pillars, 7 perspectives, and Munger lens point in the same direction?
MoonshotScore
43 / 100
multi-pillar methodology. Cash Runway strong. Revenue Growth weak.
How is it calculated? ->
Revenue Growth0.0
Q4 vs Q1: growth negative (-5.3%, contraction)
Gross Margin5.0
Q4: average margin (48.5%)
Operating Leverage2.0
op margin healthy (18.6%)
Cash Runway10.0
FCF very strong ($4.9B, 4.8x CapEx)
R&D Intensity3.0
low R&D investment (0.0%, weak innovation)
Price Momentum4.0
RSI 48.9 balanced, 50d below
News Sentiment6.0
majority buy (56%)
Council Score
2 / 6 Bullish
6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).
How is it calculated? ->
Ray Dalio macro - target upside +10.2%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 49
Klarman value - target upside +10.2%
Buffett quality - ROE score 5/5
Munger valuation - target upside +10.2%
Munger's Mindset character & balance sheet lens
Fairly Valued
Quality business, trading at fair value.
How is it calculated? ->
Interest CoverageAdequate
Technical Levels - Pre-earnings positioning
What levels is the stock being tested at?
RSI(14)
48.9
RSI 48.9 balanced, 50d below
MACD
-0.40
price below 50d - resistance dominant
50d MA
$148
stock 0.4% below - short-term resistance
200d MA
$148
stock 0.7% below - long-term pressure
Volume (10d)
-38%
decrease - low participation
Resistance
$162
Analyst median target - upgrade trigger if broken
Current
$147
Pre-earnings position
Support
$126
Invalidation - close below this is a technical breakdown
Pattern
Range
$126-$162 band - earnings breakout/breakdown trigger
Past Performance
The's last 8 quarters: 6 consecutive beats.
BEAT
Q1 FY26
$1.99 vs $1.90 est - -0.5%
BEAT
Q2 FY26
$1.88 vs $1.86 est - +0.1%
BEAT
Q3 FY26
$1.59 vs $1.56 est - +0.1%
BEAT
Q4 FY26
$1.43 vs $1.41 est - -1.5%
Q3 (April 24, 2026): EPS $1.43 vs $1.41 est[FMP], +1.4% beat. D+1 movement: -1.5%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Three scenarios: what could happen?
EPS < $1.84 (no guidance)
Q3: EPS $1.43 vs $1.41 beat[FMP], stock -1.5% D+1[FMP]. Andre Schulten Q3 transcript: "We continue to expect organic sales growth of in line to 4%."[Andre Schulten].
"We continue to expect organic sales growth of in line to 4%."
- Andre Schulten, CFO - Q3 FY26 Earnings Call - April 24, 2026
Backlog concentration
No RPO/backlog concentration disclosed in Q3 earnings call.
Insider trading signal
Form 4 data is marked in the table - this page does not generate assumptions for this stock.
Our FMP plan does not provide Form 4 insider feed for this stock. This page does not generate assumptions - SEC EDGAR Form 4 can be monitored directly.
CapEx shock
Q3 CapEx $1.0B[FMP cashflow]. Q3 op margin 18.6%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.
"This includes an increase in capital spending as we add capacity in several categories and as we incur the cash costs from the restructuring work."
- Andre Schulten, CFO - Q3 FY26 Earnings Call - April 24, 2026
Framework - Position discipline
After the data arrives: 3 scenarios, 3 windows
Not advice - a structural framework for earnings night. Decision discipline is yours.
Scenario A - Beat
Q1 EPS > $1.90 + CapEx discipline
Threshold: EPS > $1.90[FMP est].
Target: Break above median target $162[FMP target]; high target $172[FMP] upper bound.
Scenario B - In-Line
EPS approx $1.90 + CapEx < $1.0B
Threshold: EPS approx $1.90[FMP est], Q1 CapEx < $1.0B[FMP].
Target: Consolidation in the band between current $147[FMP] and median $162[FMP].
Scenario C - Miss
EPS < $1.84 or CapEx >= $1.0B
Threshold: EPS < $1.84[FMP estx0.97].
Target: Current $147 below SMA200 $148[FMP], if rejection continues, $126[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.
Market Outlook
What do 4 analysts say?
Wall Street Consensus
$162
12-month median target price (+10.2% gap to the analyst consensus median)
Risk Management
$126
Invalidation level - critical support threshold
$148 - 50-day MA (below, -0.4%)
$148 - 200-day MA (below, -0.7%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - PG Q1 FY27
B+
You read it in 5 minutes. When the numbers come out on Friday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Friday evening. The framework is ready on this page: Q1 EPS threshold $1.90[FMP], CapEx threshold "below $1.0B". Two anchors, three scenarios.
Comparison
Stock Expert AI is free today — no credit card.
3 subscriptions. 1 platform.
Seeking Alpha $299/yr - analyst opinions + earnings coverage
TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades
Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
Catalyst Calendar - 90-day forward look
Oct 23, 2026EARNINGSQ1 FY27 results (after market close) + earnings call
Oct 24, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Dec 7, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Jan 23, 2027EARNINGSQ2 FY27 (next quarter, date not yet scheduled in FMP)
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
Frequently Asked Questions
What does the PG earnings preview cover?
This The Procter & Gamble Company (PG) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
What should investors watch for in PG earnings?
The Procter & Gamble Company (PG): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Where do the numbers on this page come from?
The Procter & Gamble Company (PG): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Is this a buy or sell recommendation?
The Procter & Gamble Company (PG): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.